Tracing the origins of highly contagious and life-threatening viruses is hugely imperative for formulating preventive strategies and treatment methods in the face of future outbreaks.
A new study provides important insights on the potential origins of the most recent outbreak of viral pneumonia in China, which started in the middle of December and now is spreading to Hong Kong, Singapore, Thailand, and Japan. The findings are published online in the Journal of Medical Virology.
The study notes that the patients who became infected with the virus--a type of virus classified as coronavirus and named 2019-nCoV by the World Health Orgzation--were exposed to wildlife mals at a wholesale market, where seafood, poultry, snakes, bats, and farm mals were sold.
By conducting a detailed genetic analysis of the virus and comparing it with available genetic information on different viruses from various geographic locations and host species, the investigators concluded that the 2019-nCoV appears to be a pathogen that was formed from a combination of a coronavirus found in bats and another coronavirus of unknown origin.
The resulting virus developed a mix or "recombination" of a viral protein that recognizes and binds to receptors on host cells. Such recognition allows the viruses to enter the host cells, which subsequently leads to infection and disease.
Finally, the team uncovered evidence that the 2019-nCoV likely resided in snakes before being transmitted to humans. Recombination within the viral receptor-binding protein may have allowed for cross-species transmission from snake to humans.
"Results derived from our evolutionary analysis suggest for the first time that snake is the most probable wildlife mal reservoir for the 2019-nCoV," the authors wrote. "New information obtained from our evolutionary analysis is highly significant for effective control of the outbreak caused by the 2019-nCoV-induced pneumonia."
An accompanying editorial notes that although the ultimate control of emerging viral infections requires the discovery and development of effective vaccines and/or antiviral drugs, currently licensed antiviral drugs should be tested against the 2019-nCoV.
( With inputs from ANI )